Clinical Trials Browser

Disease Progression × Nivolumab × Gastrointestinal × Clear all

NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT03259867 2026-04-16

TATE-PD1

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Stomach Neoplasms, Disease Progression